Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma

Recruiting now · Early Phase 1

Conditions studied: Head and Neck Squamous Cell Carcinoma

In brief

This pilot clinical study will investigate if Zirconium-89 (89Zr) panitumumab- Positron Emission Tomography/ Magnetic Resonance Imaging (PET/MRI) imaging can more accurately determine size and location of primary tumors compared to standard of care Fludeoxyglucose (18F-FDG) -PET/MRI in newly diagnosed patients with head and neck squamous cell carcinoma (HNSCC) who are undergoing surgical resection. This study is for imaging purposes only and is not a treatment study. The results of this study will not change the clinical treatment plan.

Key facts

Study ID: NCT05183048
Run by: University of Alabama at Birmingham
People needed: 14
Starts: 2023-02-20
Expected to finish: 2028-02-01
Last updated by the study team: 2025-12-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Biopsy-confirmed diagnosis of squamous cell carcinoma of the head and neck
Subjects newly diagnosed with any T stage, any subsite within the head and neck that are scheduled to undergo surgical resection.
Subjects are to be staged clinically and radiographically node negative (cN0)
Planned standard of care surgery with curative intent for squamous cell carcinoma
Age > 18 years
Have acceptable hematologic status, coagulation status (11 to 13.5 seconds. international normalized ratio (INR) of 0.8 to 1.1), kidney function, and liver function including the following clinical results:
Hemoglobin ≥ 9 gm/dL
White blood cell count ≥ 3000/mm3
Platelet count ≥ 100,000/mm3
Serum creatinine ≤ 1.5 times upper reference range
alanine transaminase (ALT) (SGPT) 7-56 units/liter, aspartate aminotransferase (AST) (SGOT) 5-40 units/liter.

You may not qualify if…

Received an investigational drug within 30 days prior to the first dose of [89Zr]panitumumab.
Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment.
Previous HNSCC resection.
History of infusion reactions to monoclonal antibody therapies.
Pregnant or breast-feeding women.
Magnesium (<1.7 mg/dL) or potassium (<3.6 mmol/L) lower than the normal institutional values.
Subjects receiving Class I-A (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.
Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis.
Severe renal disease or anuria (Creatinine within normal institutional limits OR Creatinine clearance ≥60 mL/min/1.73 m2 for patients with creatinine levels).
Known hypersensitivity to panitumumab or any of its components.
Weight over 350 lbs., due to the scanner bore size.
Contraindication for MRI procedures (e.g. non-removable metal implants or certain tattoos).

Where it is running

UAB — Birmingham, Alabama, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.